Panel endorses Merck's anti-clotting drug

Share this article:

Advising the FDA to “do its due diligence” about bleeding risk, an FDA panel voted 10-1 in favor of Merck's anti-clotting drug vorapaxar, which would have the brand name Zontivity, Reuters reports. The panel and Merck want to limit the drug's use to heart attack patients without a stroke history, because of an increased bleeding risk among stroke patients.

Aspirin, and Bristol-Myers Squibb's now off-patent Plavix (clopidogrel) seek the same goal—to prevent clots—but Reuters notes Merck's potential market peer works differently, by inhibiting a PAR-1 receptor.

The panel also says the drug should come with a weight minimum because lighter patients appear to be at a higher risk for bleeds.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions